Member Info for notaflipper

Difficult to understand the 21% discount here, when the last placing was at a premium at 11p. A bit difficult to understand as well the urgency of the need and why they could not await just one further month when the FDA decision on Stage 3 is expected by the 29th. It would be helpful if TM could spell out the investment potential here otherwise confetti shares from placings will continue to scare off potential investors.

Tomorrow should be an interesting day, with an expected 50 basis points increase to 1.75% (biggest interest rate in 27 years) to choke off the highest level of inflation in 40 years. For some reason Capita seem to always target the timing of their trading updates poorly as per the December showing which coincided the day after BoJo's Covid warning which raised fears of a 3rd lock-down. We'll have to see whether this has been priced in, or whether MM's give a good shake to grab shares before a positive trading update by end of week which should confirm the debt clearance and revenue recognition figures. Let's see if an opportunity presents itself. Have to imagine that there'll be a reaction by China at some point to add to the investment woes of 2022, so at this rate tempting to bring out the tin hat and shovel and dig a bunker.

https://www.bbc.co.uk/news/business-62386909

FTSE will be positive today given that yesterday saw gains over 2% on the S&P 500 and over 4% on the Nasdaq as the Fed eases concerns over accelerating rate hikes higher. That said, Bank of England expected to raise rates by 25bps to 50bps on August 4th next Thursday, which may check any bull-run as per last month.

Though the trend may be up in the next month towards trading update, there will be some further slip back today. You
had Michael Saunders a member of the BoE's MPC has stated that interest rates could reach 2%, or higher, next year and UK unemployment coming in 3.8% in the three months to May (vs 3.9% forecasts). Added to that US struggled to find much momentum off the 7,000 area. So imagine that CPI will follow broader market trend which suggests the FTSE loosing 40 points. So can see CPI bobbing around this range or even falling into 25s but should come good by trading update.

To be fair all BBs have trolls. Also many here were spiked back during the last Phase III results. And so, you do see these spiked PIs de-ramping any positives so that they can average down.

Does it make a difference to the eventual sp here, no. It is invariably just pathetic and tiresome to read, especially when it is so obvious. In our case, we do have to appreciate that we have an incredibly active one, that even will post whilst on annual leave as mentioned last week. Unfortunately, that hiatus for us both was short-lived it seems.

Back to IMM...Some great positives in the initiation note..
https://tinyurl.com/23unwzph
"Overall, at this stage, we value ImmuPharma at 37p per share."

They also explain that the current Benchmark does allow for increased monthly funding than £91.7k when the sp is higher than the benchmark of 14.67p. So now as the sp is averaging 5.5p, ImmuPharma only receives £34.4k (37.5% of £91.7k). However what TM should be really doing is pumping up the sp. For example, if the share price is 20.0p, ImmuPharma would receive £125.0k (136% of £91.7k) for that month.

Starting to feel bit positive here, like things are finally waking up. Not long more to go. Positions placed.

Thought I went I went on the wrong board as only saw posts from posters who had decried LSE for its partisan views and said that they were only going to post on discord, and for PIs to follow them there.

@lambo If you have an opinion that there's nothing happening till September, and no positivity till then, then so be it. That a placement is upcoming in the next few weeks and will be sub-6p, when the last was at 11p is also an opinion though not shared, is your pejorative to have. The combination of the two, and posting ad nauseum for the last two day in response to the (very small positive) share price movement detracts from the authenticity of your views. No offence intended but it is a waste to read, and for you to write.

I think your exact wording was "FDA have 75 days to schedule a meeting but we cannot change how slowly the FDA work". I read that as 75 days to schedule a meeting, not for the meeting to be held and outcome known. Will have to see what the feedback is post the 29th Aug, however it does seem to me that the fact that this is being done in correspondence suggests some positivity.

Great news and pretty positive wording.

With both Sunak and Javid resigning, I suspect the market is going to start pricing in BoJo's resignation in the near term. When they were thinking that he would lose the confidence vote, sterling rose in relief. So it will be interesting to see the markets in the next few days.

Admission of new ordinary shares of £0.01 following share capital reorganisation, was expected to be around Monday 4 July 2022. Market seems to be awaiting to see impact to begin accumulation pre-FDA meeting update.

Hopefully the delay means other news is upcoming

@Drew57, my understanding is that the submission of the PK Study must be at least one month prior to the formal Type C meeting. After then, in theory the Type C meeting can be held at anytime but will have to be scheduled within 75 days of receiving the written meeting request, which is the September date. So for me that was the significance of the RNS. It looks like despite the slip back there has been no major worries of the admission of the new shares on the 04th July. The margin requirements are still quite here, which suggests some more news is expected before September, but let's see. TM continues to disappoint, sadly.

I have to hold onto the hope that the FDA state 75 days is the maximum period to await a schedule of a meeting. In theory a meeting can be held 1 month after submission of the PK Study. Bearing in mind that the Phase 3 trials were originally hoped to commence in 2021 it is a bit disappointing to say the least. The frustration here is that the Nov '21 Corporate Update stated that other news was expected in H1 2022. For example updates on BioAMB and potential commercial partnering discussions. Similarly updates on whether P140-CIDP moving into a Phase 2/3 adaptive registration clinical trial and again updates on the commercial partnering discussions. I am aware that some LTHs here date back to the start of the last Phase III and Fast Track designation by the FDA in Nov 2011.

If Avion have submitted the PK study data to the FDA via a type C meeting, then the submission must be at least one month prior to the formal Type C meeting. As mentioned the FDA will attempt to schedule all Type C meetings within 75 days of receiving the written meeting request.

Mute discussion now RNS has landed. Extract below. Will have to see what the impact on sp will be tomorrow and after the 4th July.

+++++++++++++++++++++++++++
RNS Number : 5391Q

At the AGM held earlier today, shareholders approved a resolution to sub-divide each existing ordinary share of £0.10 nominal value in the capital of the Company ("Existing Ordinary Shares")into one ordinary share of £0.01 each nominal value; and one deferred share of £0.09 each (these deferred shares have no voting rights, and no practical value).

Application has today been made for 284,984,933 ordinary shares of £0.01 ("New Ordinary Shares") to be admitted to trading on AIM. Admission is expected on or around Monday 4 July 2022

Surely they would await till after the release of FDA decision before any further fund raising.

It is not tbh. The Bid will be dropped in order to catch out the last of the margin calls before any rise up.

Wonder if there will be any news before ImmuPharma's AGM on Tuesday 28 June 2022? Hope someone calls up TM on using this as a lifestyle company with the **** poor IR communications, and a stagnant sp, which despite some strengthening this week is still near all-time lows and well below latest placing price (and Benchmark price).

Difficult to find energy even to get upset with the current sp being back to all time lows. Very poor performance after positive news of PK Study and Placing. Characteristically poor performance and communication of TM.